







## MICROGEN DIAGNOSTICS

2002 W LOOP 289, SUITE 116 | LUBBOCK, TX 79407

FAX: 1 - 407 - 204 - 1401 | PHONE: 1 - 855 - 208 - 0019

<b>PATIENT</b>		<b>SPECIMEN</b>	R MAXILLARY	<b>PHYSICIAN</b>	
<b>DOB</b>	-	<b>RECEIVED</b>	02/25/2020	<b>PHONE</b>	-
<b>PATIENT ID</b>	00000	<b>COMPLETED</b>	02/27/2020 2:08 PM	<b>FAX</b>	-
<b>GENDER</b>		<b>ACCESSION</b>	0000000	<b>COLLECTED</b>	02/21/2020

qPCR TESTS FOR BACTERIA	FUNGI	STIs	RESISTANCE GENES
None	None	None	None

## Next Generation Sequencing Results

MicroGen Diagnostics' comprehensive testing (patent pending) is a relative quantitative universal test for bacteria/fungi. DNA sequencing methods are used to identify the microorganisms' genetic signatures and the estimated percentage of organisms present in the specimen. Virtually all bacteria/fungi are screened for in a CAP and CLIA accredited laboratory and the most predominant populations are reported.

ANTIBIOTIC CLASSES AND MOST-COMMONLY USED EXAMPLES			
CLASS	GENERIC formulations	CLASS	GENERIC formulations
Allylamines	Amorolfine; Naftifine	Flucytosine	5-fluorocytosine (Ancobon)
Aminoglycosides	Gentamycin; Tobramycin	Fluoroquinolones	Norfloxacin(PO); Levofloxacin;
Aminoglycosides+Aminopenicillins	Ampicillin/Gentamicin		Oxaxloxacn(PO); Ciprofloxacin(PO)
Aminopenicillins	Amoxicillin; Ampicillin(PO)	Glycopeptides	Vancomycin; Teicoplanin
Antifolates	TMP/SMX	Imidazoles	Ketoconazole(PO); Clotrimazole;
Anti-Pseudomonal Penicillins	Piperacillin; Nafcillin		Oxiconazole
Anti-Pseudomonal penicillins/Beta-lactamase inhibitors	Piperacillin/Tazobactam	Lipopeptides	Daptomycin
Anti-tuberculosis	Isoniazid; Rifampin; Streptomycin	Macrolides	Erythromycin; Azithromycin(PO)
Aztreonam	Azactam	Naphthyridones	Nalidixic acid
Carbapenems	Cilistatin/Imipenem; Meropenem	Oxacephems	Moxalactam
Cephalosporins First Gen	Cephalexin(PO); Cefazolin	Penicillins	Penicillin G; Penicillin V(PO)
Cephalosporins Fourth Gen	Cefepime	Polyenes	Natamycin; Amphotericin B
Cephalosporins Second Gen	Cefprozil; Cefotetan	Polyenes+Flucytosine	Amphotericin B/5-fluorocytosine
Cephalosporins Third Gen	Cefixime; Cefdinir; Ceftazidime	Tetracyclines	Doxycycline(PO); Minocycline
Cephameycins	Cefoxitin	Triazoles	Fluconazole(PO); Terconazole
Echinocandins	Caspofugin; Micafungin	Triazoles+Echinocandins	Voriconazole/Anidulafungin
Extended spectrum penicillins / Beta-lactamase inhibitors	Amoxicillin / Clavulanate(PO); Ampicillin / Sulbactam		

## Complete Antibiotic Analysis

ANTIBIOTIC DISCLAIMER: Southwest Regional PCR, DBA MicroGen Diagnostics, LLC assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this antibiotic report. Therapeutic options listed by the program are based upon national antibiotic susceptibility data and antibiograms. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the database is curated and derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and regions of the country. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. Although we endeavor to include such new information on a timely basis, a delay cannot be avoided. For more information please contact us at 855-208-0019.

DISCLAIMER: (i) This test was developed and performance characteristics have been determined by Southwest Regional PCR Laboratory dba MicroGen DX. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA), however, the FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. Its use should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88) as qualified to perform high complexity clinical laboratory testing. (ii) A negative result does not rule out the presence of PCR inhibitors, or DNA extraction inhibitors such as lidocaine, in patients' specimens or microbial DNA concentrations below the level of detection of the assay. (iii) This test is performed pursuant to an agreement with Roche Molecular Systems, Inc. (iv) Relative quantitation of swabs refers to analyte load levels of  $< 10^5$ ,  $10^5$  to  $10^7$ , and  $> 10^7$  for low, medium and high respectively. Southwest Regional PCR Laboratory dba MicroGen DX licenses are CLIA 45D1086390 and CAP 7214171.

## ANTIBIOTIC ANALYSIS

This antimicrobial recommendation sheet is not based on antibiotic sensitivities but is based on antimicrobial reference guides such as the John Hopkins ABX Guide.